Program
amrubicin
Also written as “Amrubicin”, “Amrubicin Hydrochloride” and “Amrubicin (Japan only)”.
Its studies are mostly in Small Cell Lung Carcinoma · Lung Neoplasms · Breast Neoplasms, led by 3 companies.
Drug pageAmrubicin: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibbits history only | 60 open or running | phase 3since Oct 18, 2007 | Apr 27, 2006 | none ahead |
| Sumitomo Pharmaits history only | 20 open or running | phase 3since Feb 1, 2006 | Feb 1, 2006 | none ahead |
| Gilead Sciences | 11 open or running | phase 3since Jan 24, 2025 | Jan 24, 2025 | Oct 2029phase 3 · NCT06801834 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Gilead Sciences only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 24, 2025First study: phase 3 study in Extensive Stage Small Cell Lung Cancer (ES-SCLC)First studyNCT06801834 · 695 planned · United States, Argentina, Australia and more
Ahead
- Oct 2029Primary completion: phase 3 study in Extensive Stage Small Cell Lung Cancer (ES-SCLC)NCT06801834
TargetBeta
“DNA topoisomerase II alpha inhibitor; DNA topoisomerase II alpha inhibitor”ChEMBL 37, by rule
Other programs on TOP2A
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Doxorubicinrule | Hoffmann-La Roche | phase 4 | 61 |
| Etoposiderule | Hoffmann-La Roche | phase 3 | 28 |
| Daunorubicinrule | kura-oncology-inc | phase 3 | 7 |
Studies
The one study Gilead Sciences leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06801834Extensive Stage Small Cell Lung Cancer (ES-SCLC) · United States, Argentina, Australia and more | 3 | Recruiting | Oct 2029 | 695 |
How it is read
Names in the registry
- “Amrubicin”, 6 entries
- “Amrubicin Hydrochloride”, 2 entries
- “Amrubicin (Japan only)”, 1 entry
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 6 studies
- Lung Neoplasms, 1 study
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.